Practical Considerations on the Measurement of Low Molecular Weight Heparin Anti-Xa Activity

Aiach, Martine; Roncato, M

doi:10.1055/s-2007-1004366

Cited by 8 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the human subject, injection of enoxaparin does not cause any significant prolongation of the activated partial thromboplastin time or of the thrombin time (TT) when compared with unfractionated heparin 18 , 19 . The effect on IIa activity compared with that of unfractionated heparin at equal anti‐Xa levels gives a ratio of 4:1 20 . On an equivalent weight basis 1 mg of enoxaparin has the same anti‐Xa activity as 0.67 mg of unfractionated heparin and the same anti‐IIa activity as 0.15 mg of unfractionated heparin 20 .…”

Section: Mode Of Action Of Lmw Heparinsmentioning

confidence: 99%

“…The effect on IIa activity compared with that of unfractionated heparin at equal anti‐Xa levels gives a ratio of 4:1 20 . On an equivalent weight basis 1 mg of enoxaparin has the same anti‐Xa activity as 0.67 mg of unfractionated heparin and the same anti‐IIa activity as 0.15 mg of unfractionated heparin 20 . Thus following subcutaneous injection in man in doses of 20–80 mg, maximum anti‐Xa activity was achieved in three to four hours.…”

Section: Mode Of Action Of Lmw Heparinsmentioning

confidence: 99%

See 1 more Smart Citation

Prevention of deep vein thrombosis — use of the low molecular weight heparin enoxaparin

Forbes

1989

Int J Clinical Practice

View full text Add to dashboard Cite

Section: Mode Of Action Of Lmw Heparinsmentioning

confidence: 99%

Section: Mode Of Action Of Lmw Heparinsmentioning

confidence: 99%

Prevention of deep vein thrombosis — use of the low molecular weight heparin enoxaparin

Forbes

1989

Int J Clinical Practice

View full text Add to dashboard Cite

“…Anti-factor Xa tests (39,(55)(56)(57)(58)(59)(60)(61)(62). Like 4, but now with factor Xa rather then with thrombin.…”

mentioning

confidence: 99%

The determination of heparin in blood

Hemker¹,

Béguin²

1990

Fibrinolysis

View full text Add to dashboard Cite

The Antithrombotic Activity and Pharmacokinetics of Enoxaparine, A Low Molecular Weight Heparin, In Humans Given Single Subcutaneous Doses of 20 to 80 mg

Frydman¹,

Bara²,

Roux³

et al. 1988

The Journal of Clinical Pharma

172

View full text Add to dashboard Cite

The pharmacokinetics of enoxaparine, a low molecular weight heparin, was randomly studied in 12 healthy male volunteers. Doses of 20, 40, 60, and 80 mg were injected subcutaneously in randomized cross-over fashion. Anti-IIa and anti-Xa activities (using amidolytic methods), and calcium thrombin time, were measured over 36 hours. The maximum Amax of the anti-IIa and anti-Xa activities appeared 3 to 4 hours after administration. The terminal half-lives of anti-IIa and anti-Xa activities were approximately 2 and 4 hours, respectively, with no significant variation between the different doses. For the anti-Xa activity, there was a highly significant positive correlation between the dose injected and individual values of Amax (r = +0.915; P less than .001) and AUC (r = +0.913; P less than .001). Enoxaparine displays a relatively small apparent volume of distribution (about 7.0 L) and its total body clearance is about 1.25 L/hr. The mean residence time ranges from 4.6 to 7.6 hours. Thus, the pharmacokinetic profile of enoxaparine is characterized by a linear relationship between dose and absorption, a relatively low clearance and long elimination half-life, and a high anti-Xa/anti-IIa ratio.

show abstract

Practical Considerations on the Measurement of Low Molecular Weight Heparin Anti-Xa Activity

Cited by 8 publications

References 20 publications

Prevention of deep vein thrombosis — use of the low molecular weight heparin enoxaparin

Prevention of deep vein thrombosis — use of the low molecular weight heparin enoxaparin

The determination of heparin in blood

The Antithrombotic Activity and Pharmacokinetics of Enoxaparine, A Low Molecular Weight Heparin, In Humans Given Single Subcutaneous Doses of 20 to 80 mg

Contact Info

Product

Resources

About